A5004011545- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Phagocytosis and Immune Regulation
- Lymphoma Diagnosis and Treatment
- Antifungal resistance and susceptibility
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Eosinophilic Disorders and Syndromes
- Transplantation: Methods and Outcomes
- Retinoids in leukemia and cellular processes
- Histone Deacetylase Inhibitors Research
- Pancreatic and Hepatic Oncology Research
- Ubiquitin and proteasome pathways
- Infectious Diseases and Mycology
- Brain Metastases and Treatment
- Occupational and environmental lung diseases
- Peptidase Inhibition and Analysis
- Amyloidosis: Diagnosis, Treatment, Outcomes
Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo
2016-2025
Icahn School of Medicine at Mount Sinai
2022
Carle Foundation Hospital
2008
Azienda Ospedaliero Universitaria San Giovanni Battista
2007
Fondazione Gimema Onlus
2004
University of Genoa
2001
The purpose of our study was to evaluate the incidence and outcome invasive fungal infection (IFI) among patients who underwent autologous or allogeneic hematopoietic stem cell transplantation (HSCT) at 11 Italian centers.This cohort-retrospective study, conducted during 1999-2003, involved HSCT admitted tertiary care centers university hospitals in Italy, developed IFIs (proven probable).Among 3228 (1249 recipients 1979 recipients), IFI occurred 121 (overall incidence, 3.7%). Ninety-one...
Short imatinib pulses were added to chemotherapy improve the long-term survival of adult patients with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL), optimize complete remission (CR) and stem-cell transplantation (SCT) rates.Of 94 total (age range, 19 66 years), 35 represented control cohort (ie, imatinib-negative [IM-negative] group), 59 received 600 mg/d orally for 7 consecutive days imatinib-positive [IM-positive] starting from day 15 course 1 3 before during...
Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets patients lacking, especially relapsed or refractory leukemia.AVALON a multicentric cohort study that was conducted Italy AML who received venetoclax-based therapies from 2015 to 2020. The approved by ethics committee participating institution and accordance Declaration Helsinki. effectiveness toxicity venetoclax + HMA 190 (43 newly...
Highlights•Minimal residual disease positivity in acute lymphoblastic leukemia is a major risk factor for relapse and poor outcomes•We evaluated the impact of minimal levels before allogeneic hematopoietic stem cell transplantation on outcomes patients with Philadelphia chromosome–positive leukemia•Patients measurable have higher relapse•Achieving negativity should be prerequisite successful transplantationAbstractAllogeneic (alloHSCT) first complete remission (CR1) remains consolidation...
Early recognition of Ph-like acute lymphoblastic leukemia cases could impact on the management and outcome this subset B-lineage ALL. To assess prognostic value status in a pediatric-inspired, minimal residual disease (MRD)-driven trial, we screened 88 ALL negative for major fusion genes (BCR-ABL1, ETV6-RUNX1, TCF3-PBX1 KTM2Ar) enrolled GIMEMA LAL1913 front-line protocol adult BCR/ABL1-negative The screening - performed using BCR/ABL1-like predictor identified 28 (31.8%), characterized by...
Positive Platelia Aspergillus test results were observed in consecutive serum samples from an immunocompromised host during amoxicillin-clavulanic acid treatment, and a correlation between plasmatic amoxicillin concentration galactomannan optical density index was observed. Amoxicillin-clavulanic vials tested positive for but negative DNA.
Abstract An updated strategy combining pediatric-based chemotherapy with risk-oriented allogeneic hematopoietic cell transplantation (HCT) was evaluated in Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph− ALL) and compared a published control series. Following induction–consolidation chemotherapy, responsive patients were assigned to receive maintenance or undergo early HCT according the risk stratification criteria minimal residual disease (MRD) status. Of 203 study...
Pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/LL). In LAL1913 trial, Gruppo Italiano Malattie EMatologiche dell'Adulto added pegaspargase 2000 IU/m2 to courses 1, 2, 5, and 6 an 8-block protocol patients aged from 18 65 years, dose reductions in >55 years. Responders were risk stratified allogeneic hematopoietic cell transplantation (HCT) or maintenance per clinical...
We evaluate the long-term results of a prospective clinical study enrolling more than 100 adult patients with Burkitt lymphoma/leukemia. Depending on extent disease, treatment consisted six to eight rituximab infusions and four courses intensive chemotherapy (attenuated in aged >55 years) high-dose methotrexate, fractionated ifosfamide/cyclophosphamide, other drugs rotation, intrathecal chemoprophylaxis. One-hundred five were treated (median age 47 years, range 17–78 years); 48% had...
Abstract Background Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B‐cell acute lymphoblastic leukemia (B‐ALL) but real‐world data are limited. Methods The INO‐CD22 study is a multicenter retrospective cohort of adult patients with relapsed/refractory B‐ALL treated IO 24 Italian centers from 2014 2019, aim assessing response, survival, and toxicity IO. Results Data for 73 eligible were obtained: median age at start was 52.7 years (I–III quartiles, 51.9–53.5 years),...
Abstract Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib an orally bioavailable, potent, highly selective inhibitor AXL, a receptor tyrosine kinase associated prognosis, chemotherapy resistance and decreased antitumor immune response. We report bemcentinib monotherapy bemcentinib+low-dose cytarabine combination therapy arms from completed BerGenBio-funded open-label Phase 1/2b trial...
Summary This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years. Three hundred and one AML were to receive DNR (45 mg/m 2 days 1–3) or DNX (80 plus cytarabine (AraC; 100 1–7). Patients complete remission (CR) received a course same drugs as consolidation then for maintenance with AraC+ all trans retinoic acid no further treatment. Among 153 arm, 78 (51·0%) achieved CR, 55 (35·9%)...
We report two cases of Acremonium fungemia with proven involvement the skin and probably lung in patients who were both undergoing chemotherapy, one for mantle cell lymphoma other acute lymphoblastic leukemia. Both failed amphotericin B deoxycholate treatment successfully treated voriconazole very mild toxicity.